Latest Commercial Rollouts News

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

EVE Health Group has completed its acquisition of Nextract, raised $1 million to fund manufacturing, and achieved key regulatory and commercial milestones for its pharmaceutical products targeting erectile dysfunction and dysmenorrhea.

Knosys Limited sustains a robust $9.8 million Annual Recurring Revenue, extends its ANZ Bank contract, and accelerates AI-driven library technology development with promising early market feedback.

BCAL Diagnostics has reported strong early commercial uptake of its BREASTEST plus non-invasive breast cancer diagnostic test, alongside a new partnership with Cancer Care Associates to expand market reach.

Nanoveu Limited has accelerated its commercial and technological momentum with a $3.02 million capital raise, a breakthrough 33% increase in drone flight time using its edge-AI chip, and progress toward a U.S. OTCQB listing.

Proteomics International Laboratories has secured $12 million to fast-track its precision diagnostic tests, including the US launch of PromarkerD for diabetic kidney disease, backed by a new AMA billing code. The company also advances its pipeline with new patents and commercial partnerships.

Adherium Limited has appointed seasoned medtech executive Dawn Bitz as CEO to spearhead the expansion of its Hailie® respiratory monitoring platform, with a strong focus on the US market.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

PainChek has completed its final FDA submission for the PainChek Adult App, targeting the US long-term care market with a potential $100 million annual opportunity. A regulatory decision is expected within 75 days, setting the stage for rapid commercialisation.

Metallium Ltd has completed a A$50 million institutional raise, secured a Texas site, and validated its commercial Flash Joule Heating reactor, setting the stage for its first U.S. metals recovery plant commissioning by year-end 2025.

dorsaVi confirms its licensed 40nm Resistive RAM technology delivers high-speed, low-power performance ideal for next-generation embedded and edge AI platforms. This breakthrough supports advanced wearable sensors and neuromorphic computing applications.

Nanoveu Limited has raised A$2 million through a strategic placement to accelerate the commercialisation of its 16nm ECS-DoT chip and expand its EMASS modular AIoT platform, positioning the company for global growth.